All Episodes
BioSpace — 248 episodes
The future of pain relief: Exploring opioid alternatives
Biogen validates anti-tau approach at AAIC, psychedelics full speed ahead, ATTR-CM shakeup
Bonus: Q2 2026 Job Market Update
From sequence to scale: Gene editing’s new era in biologics manufacturing
Vertex carries M&A uptick into H2, IPOs and VC raises also grow, FDA on pace despite turmoil
Sentiment at BIO soars as FDA resets, dealmaking evolves; Amgen’s Tavneos in hot water
The Golden Triangle and the gaps: Rethinking UK biotech
AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more
From fragile skin to living medicine: Lessons from RDEB
Moderna’s FDA adcomm, IPO mania, biopharma layoffs, more
Portugal, Spain and the new biotech frontier
Lilly tees off with Novo at ADA, GSK’s $10.6B deal, FDA reform continues in Makary’s absence
Rethinking hair loss treatment
ASCO wins from RevMed, Akeso/Summit, more; plus more Lilly and more China; ADA on deck
France’s biotech ecosystem: science, capital and scale
Lilly wheels and deals, Moderna gets boost on hantavirus scare, ASCO excitement builds
Inside Germany’s biotech capital infrastructure and innovation engine
FDA’s absent leaders, the millions pharma CEOs make, and pancreatic cancer’s momentum
From MSCs to iPSCs: building the cell therapy future
Makary’s out at FDA, Sanofi’s priority voucher issues, top exec pay
Fibrosis, IPF and the search for better therapies
Pfizer, Lilly, more report Q1, FDA names acting CBER director and an ALS awakening
What makes life science angel investment work?
Q1 earnings take off, Lilly strikes deals, Regeneron notches historic approval, FDA raises questions
The next era of diabetes management
Trump’s psychedelics push, Lilly’s up to $7B CAR T deal, Replimune’s saga and Denali’s big win
Funding the Future of European Biotech
J&J targets $100B revenue, Replimune rebuffed again and a “Revolution” in pancreatic cancer
Bonus: Q1 2026 Job Market Update
Automation, Collaboration and the Future of Advanced Therapies
Lilly’s Foundayo Nod Launches New Battle With Novo, M&A Mania Continues, Tariffs Hit Pharma
The Radiotherapeutics Moment: How Isotopes are Changing Cancer Treatment
Biopharma M&A Heats Up, Rare Diseases Win Three Approvals, Wave Crashes
Beyond Buzzwords in Longevity Investing
Gilead’s Ouro Buy, J&J/Protagonist’s Approval, Aurinia’s Revamp, ACIP Confusion, More
Inside the Race to Build the Next Generation of AI Drug Discovery Platforms
Kennedy’s Vaccine Agenda Stalled, Structure’s ‘Competitive’ Obesity Pill, Novo’s Warning Letter
From Two Trials to One, Sponsors Face a Higher Standard
Prasad Out at FDA, Lawmaker Takes Action on Rare Disease Rejections and a Spate of Obesity Data
Rising Amid Flurry of CAR T Deals, Stylus Proves Cell Therapy Is Not Dead
From Grants to Family Offices: Building a Unified Financing Strategy in Biotech
UniQure’s Delay, REGENXBIO’s Rejection Explained, Sarepta’s Ingram Steps Down, More
ALS Advances Unite Patients and Pharma on Novel Targets, Biomarker Breakthroughs
Lilly Bests Novo Again, Rare Disease Week Goes Regulatory, More CDC Leadership Upheaval
Corsera Eyes Two-Pronged Approach To Tackle Leading Cardiovascular Killer
Redefining Obesity Treatment Beyond GLP-1 Limits
Modernagate Fallout, Disc’s Rejection, Compass’ Psilocybin Data, CDC’s Lost Leaders
As FDA Moves Away From Animal Testing, AI and Organoids Can Shine
Digital Pathology, AI and the Future of ADCs and HER2 Cancer Treatment
Weight Loss Drama Compounds on Heels of Novo, Lilly Earnings, Plus Gene Therapy News
Programmable RNA 2.0: Beyond the First mRNA Revolution
Pfizer’s Metsera Data, 2025 Earnings, the FDA and REGENXBIO, Psychedelics and IPOs
Biotech’s New Cycle, JPM Deal Hype and Where Alpha Still Hides
Roche Makes Obesity Splash, Moderna Cans Vaccine Trials, Sarepta’s New Data, More
From Sound Bites to Signals: Editors Parse Executive and Investor Chatter at JPM
JPM26 Recap, Novo’s Oral Wegovy Soars as Lilly’s Orforglipron Is Delayed, IPOs Return
Bonus: Q4 2025 Job Market Update
Deals Roll at JPM26, Policy Front and Center, IPOs Are Back, FDA Stays Busy
From Nuclear Winter to Renewal: Biotech Investing for 2026
Novo Launches Oral Obesity Pill, Lilly Targets Lofty Revenue, FDA and M&A in Focus
Inside the 2026 Biotech Landscape: Innovation, Investment and Global Momentum
Lilly’s Triple Triumph, Prasad’s COVID Error, J&J’s Surprise Voucher, M&A Targets
Beyond the Gluten-Free Diet: A New Era in Celiac Disease Treatment
Weight Loss Waves, Pazdur’s Exit and FDA Instability, New Neuro Breakthroughs
New Approach Methodologies: Redefining Animal Testing Alternatives
Prasad’s Leaked FDA Memo, Alzheimer’s Ups and Downs, Next-Gen Obesity Drugs
Billions More in M&A, Another Bidding War and More FDA Drama
How Biotech Funding is Changing Executive Search and Hiring Processes
Pfizer Wins Metsera, Trump Strikes GLP-1 Pricing Deal, FDA Awards More Priority Vouchers
Thoughtful Tech: How Removing Technological Burdens Can Improve Clinical Trial Compliance and Patient Experience
Pfizer and Novo Battle Over Metsera, Tidmarsh Fights FDA Exit, UniQure and Sarepta Face Setbacks
Innovation, Resilience, and the Future of Global Manufacturing
Novartis’ Big Buy, Q3 Earnings, Regeneron’s Dropped Cell Therapy, More
How Supply Chain Turbulence is Reshaping Biotech Strategy
Novo Board Upended, ESMO Excitement, FDA Awards, Replimune’s U-Turn
Cost Control to Capability Building: Rethinking Supply and Strategy in Pharma
Work Smart, Build Trust: Connecting Technology, Patient Compliance and Data Processing
Q3 Earnings Are Here, Novo Ditches Cell Therapy but Buys Akero, Gov’t Shutdown Hits CDC
Bonus: Q3 2025 Job Market Update
Shutdown Pauses New Drug Reviews, CDC Issues New COVID Guidance, CGT Meets on Mesa
Hit Me With Your Best Shot: Understanding Autoinjectors and Combination Drug Delivery Systems
M&A Picks Up, Walmsley Moves On, Pfizer’s MFN Deal and Hope for Huntington’s
FDA’s Autism Endeavor, Pfizer’s Obesity Comeback Bid, Psychedelics Revival, ACIP Confusion, More
What Do AI and Hammers Have in Common?
China Crackdown, UK Exit, Novo Layoffs, Adcomm Flip Flop, More
Unpacking the Latest MAHA Report, RFK’s Senate Appearance, FDA’s CRL Drop and More
The 'Research Safety Net' Saving Scientists from Funding Crisis
CDC Faces Critical Meetings Amid COVID Vaccine Uncertainty, Plus Deals, FDA Approvals, More
Lilly’s Obesity Pill Heads to the FDA, AbbVie Bets on Psychedelics, HHS Unveils More Change
Oral Weight-Loss Race Heats Up as New Data From Lilly, Viking Reset Expectations
Why AI Won't Save the 90% of Clinical Trials That Still Fail
MAHA Report Emphasizes Vaccines, Safety Vexes Viking’s Obesity Win, Novo Gains Momentum
The Hidden Patent Crisis That Could Break Biotech: What Every CEO Needs to Know
Prasad Returns, Delany Departs, Lilly’s Weight Loss Pill Disappoints and Sarepta’s Fallout Continues
From Chat Bots to World Order: The Race for the 21st Century's Operating System
FDA In Flux, Pfizer Talks to Trump on MFN, Merck Cuts 6K Jobs, More
We Don't Own Patient Data–We're Just Babysitting It
Sarepta Gets Reprieve, RFK Jr.’s New Changes, Roche’s Alzheimer’s Comeback and Q2 Earnings
Sarepta’s Wild Week, CDER’s New Leader, FDA Rejections, Manufacturing Billions
Why Countries Are Racing to Build mRNA Factories While America Hesitates on Next-Gen Vaccines
AI Is Taking Over Drug Safety Monitoring–But There's One Thing It Can't Replace
FDA Layoffs, 200 Rejection Letters, User Fees and Priority Vouchers, Bad Week for Rare Disease
Bonus Episode: Q2 2025 Job Market Update
The mRNA Revolution You Haven't Heard About: From Cystic Fibrosis to Personalized Cancer Vaccines
Second Half Milestones, KalVista’s Surprise Approval, Another RFK Jr. Lawsuit, More
CAR T Expands, M&A Ticks Up, Two Psychedelics Read Out, and the Supreme Court Rules on PrEP
Understanding the FDA's AI Guidance in Pharmacovigilance
FDA Churn Continues, RFK Faces Congress, Obesity Insights at ADA, BIO2025 Recap
Navigating Funding Freezes and AI Frontiers
Another Gene Therapy Death; Biopharma M&A Picks Up; a Vaccine Board of Vaccine Skeptics
RFK Axes CDC Vaccine Advisors ; Metsera’s Weight Loss Win; FDA Supports CGT
AI's Role in Decoding the FDA's New Regulatory Communications
M&A Ticks Up, ASCO Excites and Vaccines Cause More Drama
COVID-19 Vaccine Overhaul, Rocket Grounded, ‘One Tough Hombre’ on MFN
How Target Product Profiles Guide the Industry Through Uncertain Times
Pfizer’s $6B China Deal, Drug Pricing and FDA’s New COVID Vaccine Plan
Trump’s Drug Pricing Policy, Prasad’s CBER Nod, Bayer’s Layoffs and Galapagos’ Next Chapter
Eroding Immunity: Vaccine Hesitancy and Cynicism
Trump’s US Manufacturing Push, New Vaccine Policy, Novo’s Weight Loss Pill up for FDA Review
Tariffs Continue to Dominate Q1 Earnings, AACR Excites Cancer Space, CEO Pay Gaps, More
Economic Challenges, Strategic Investments: Reshaping the Women's Health Landscape
Makary’s First Interview, US Manufacturing Push and Lilly vs. Novo in Obesity Pill Race
Tariff Turmoil, FDA’s Future, Pfizer’s Obesity Setback and CEO Salaries Revealed
Bonus: Q1 2025 Job Market Update
Breaking Down Barriers: The Nuanced Approach to Women's Representation in Medical Research
Tariff-Triggered Recession Fears, Fallout From HHS Cuts, Knockoff GLP-1s and More
FDA on Fire, Novo’s Mixed Bag of Semaglutide Cardio Data, Kisunla’s EU Miss, More
Balancing Protection and Inclusion: The Evolution of Women in Clinical Trials
Trump’s Pharma Tariffs, Monarez for CDC, Novo’s New Obesity Play, More
Sarepta’s Elevidys Death, FDA’s Vaccine Move, Weldon Whiplash, PDUFAs in Cardio
A Conversation With Mark McKenna, CEO of Mirador
“Perfect Patient” Industry Burdens; Exits and Investment in Women’s Health
COVID Reflections, Novo’s Next-Gen Weight Loss Struggles, Another Depression Miss, More
Tariff Threat Continues, More Meetings Cancelled, AbbVie Makes Obesity Play, More
A Conversation With Kevin Marks, CEO of Delphia
Money Meets Medicine: A Disruptor's Guide to Life Sciences Investment
Trump’s Pharma Tariffs, Another GLP-1 Compounding Lawsuit, Bluebird’s Bailout, More
Examining Gene Therapies, Bispecific Antibodies and Other Novel Modalities
Trump’s Hammer Hits FDA, Moderna Falls Further and Patent Cliffs Loom
A Conversation With Dannielle Appelhans, CEO of COUR
Navigating Patient Journeys with Tom Whitehead
New M&A Action, BMS’ Ongoing Cost Cuts and the Insatiable Demand for Weight Loss Drugs
RFK Jr. Advances, Q4 Earnings Roll Out and a Non-Opioid Pain Drug Hits the Market
The Patient's Perspective with Tom Whitehead
RFK Jr. Faces the Senate, Sage Rebuffs Biogen, Obesity Space Expands, More
Trump Takes Over, Wegovy Still Trails Zepbound and BioSpace Recaps JPM
Bonus: Q4 2024 Job Market Update
A Conversation with Peter Marks: Insights into GenScript Biotech Forum 2025
Dispatches From JPM, Biogen’s Sage Buyout Offer, Pfizer’s Obesity Play, More
A Conversation with Peter Marks and Tom Whitehead: Insights into GenScript Biotech Forum 2025 (Teaser)
NextGen Class of 2025, M&A Uptick Predicted Heading Into JPM, FDA Decisions to Watch
Trials and Capital: Women’s Health and APAC's Healthcare Revolution
Analysis vs Beliefs, CEO Challenges, GLP-1 Investments
Biopharma’s Manufacturing Push and Other 2024 Trends
Highlights From ASH, Lilly and Novo’s Manufacturing Boon, Momentum in Neuro, More
Previous Investment Patterns Set to Repeat in 2025
Biopharma’s Shopping Spree, Applied Crashes on Rejection, Skysona’s Safety Concerns, More
BridgeBio’s ATTR-CM Approval, Cassava’s Alzheimer’s Failure, Trump’s Cabinet Picks, More
51%: The Untapped Market
RFK Jr.’s HHS Nomination, Biogen’s Lupus Win and Leqembi Struggles, Neurogene’s Rough Month, More
AbbVie’s Surprise Schizophrenia Flop, AstraZeneca’s China Drama, Hope in Huntington’s, More
Investing in AI: Benefits, Regulatory Challenges
Lilly’s Q3 Miss, Novo’s MASH Win, CAR T’s Autoimmune Pivot, More
Pfizer’s Q3 Earnings Win, Deals Galore, Countdown to Election, More
Steady But Slow: Future Outlook for Investment
Trodelvy’s Bladder Cancer Withdrawal, Sage Therapeutics Layoffs, Sanofi’s Radiopharma Investment, More
Q3 Earnings Kick Off With J&J, Bluebird in Tough Spot, Novo-Catalent Deal Under Fire, More
How AI Could Ease Tension in Clinical Trials
BioSpace at Meeting on the Mesa, WuXi Considers Selling U.S. Facilities, Big Pharma Layoffs, More
BMS’ Schizophrenia Approval, Pfizer’s Sudden Sickle Cell Withdrawal and Roche’s Pharma Day
AI Return on Investment: Just Because We Can, Should We?
Novo Grilled By Senate, PhRMA’s IRA Win and BMS’ KarXT Awaits Approval
Sickle Cell Gene Therapies Reach Patients, Moderna Cuts, Obesity Pill Race and ESMO 2024
AI Promises: Funding Data Literacy and Reality First
BioMarin Fails to Reassure Investors, Terns Moves Forward in Obesity, ESMO Excitement
Lilly’s DTC Obesity Push, Layoffs, and an Eye on Ocular Diseases
Future-Proofing: Inclusive and Protective Patient Strategies
A Tough Ending, New Beginnings and China-U.S. Biopharma Relations
New IRA Drug Prices, Lots of Layoffs, Moderna’s Vaccine Opportunity
Eyes Wide Open: Gaining Patient Trust in the Face of Evolving Women’s Health Policies in State Legislations
Lykos Rejection, Pfizer’s RSV Win, Lilly Vs. Novo and More
Pharma Campaign Contributions, Vaccine Hiccups and Lykos’ Moment of Truth
The Political Shape of the Future Clinical Trial Space
2 Earnings Bonanza, M&A Accelerates and Alzheimer’s Data
Layoffs Persist, GLP-1s Launch for Weight Loss in China
Who Is Driving The Bus - Drug Developers & Healthcare Providers or AI?
Pfizer’s Oral GLP-1 Push, Lilly Vs. Novo and PBMs Under Pressure
Lilly’s I&I Play, ADC Investment and GLP-1 Momentum Persists
FDA Approves Lilly’s Donanemab While Rejections Highlight Manufacturing Issues
DE&I: Understanding That We Don’t Understand at Molecular Level
Sarepta’s Big DMD Approval, Alnylam’s Clinical Win and ADA Highlights
BioSpace at #DIA2024: Workforce Trends, Trial Design, Peter Marks & Recap
Challenging Research Models to Improve Health Equity
BIOSECURE’s Surprise Absence, the $100+ Billion Future Weight-Loss Market, DIA and More
BioSpace at #DIA2024: Convergence and Collaboration
Donanemab’s Promise, BIO Wrap and Mass Layoffs
BioSpace x DIA: Robust Integrated Regulatory Strategies
The ABCs of Biopharma This Week: ASCO, BIO and Cancer
BioSpace x DIA: Advanced Therapy Product Regulatory Confusion
AstraZeneca’s Ambitious Target, Pharma Layoffs Continue and ASCO
BioSpace x DIA: Navigating the Emergence of CGT Combination Products
Bayer’s New Strategy, Novo Vs. Lilly and Psychedelics
Bayer Layoffs, a Big Alzheimer’s Deal and ASGCT Wrap
Women's Health: Where Politics and Science Meet
ASGCT, Adcomm for Lilly’s Donanemab, Vertex Vs. Bluebird
BioSpace Heads to #ASGCT, Along with Thousands in Cell and Gene Therapy
The IRA, BMS’ Big Cuts, First WHIM Approval
Where Do We Go From Here? The Future of Women's Health
Sanofi Layoffs, CAR-T Warnings and a New GLP-1 Player
Amylyx and ALS, Continued ADC Excitement, Dire Drug Shortages
It's a Design Problem: Women and Clinical Trials
Alphabet Soup: AACR and ACC Dominate Headlines This Week
Did WuXi Make a Whoopsie? US-China R&D Relations in Limbo
Will the IRA’s Focus on the Pharmaceutical Industry Hurt the World’s Healthcare System Instead of Helping Patients?
Bayer’s sweeping executive cuts, Wegovy’s expanding reach
Money talk: Salary trends and raises
Historic approval for MASH, CAR-Ts in the spotlight
The unintended consequences of small molecules
The skinny on weight loss, donanemab and the State of the Union
The ABCs of ADCs: Why antibody-drug conjugates are so hot right now
The gap is where the pain is: Drug pricing and patient costs
Sweet succession: Gonzalez, patent thickets and his triumph over biosimilars
Iovance wins with Amtagvi and the ADC train chugs on
Eyes on the prize: Novo buys Catalent
Balancing act: Patient access and innovation
Keep calm and CAR-T on?
What can biopharma expect from the job market?
Grab an umbrella, it's raining IPOs!
Optimistic, but for how long? Our big takeaways from #JPM2024
On the ground at #JPM2024 - Day 3 highlights
On the ground at #JPM2024 - Day 2 highlights
On the ground at #JPM2024 - Day 1 highlights
Alternative funding strategies to discuss at JPM with Halia Therapeutics, the ADDF and Triumvira Immunologics
The top life sciences startups to watch this year
What VCs look for when investing with MPM Capital, Endeavor Venture Fund and Two Bear Capital
Every move you make: Biopharma industry under heavy scrutiny
What VCs really think of the market right now with MPM Capital, Endeavor Venture Fund and Two Bear Capital
Major FDA approvals for Vertex/CRISPR; bluebird gets black box warning and price scrutiny
Fast and furious evolution: How to ensure AI is catalyst for positive societal change with Microsoft and IQVIA
Integrating AI in life sciences to change employee behavior with Microsoft and IQVIA
GLP-1 and ADC rollercoasters pick up speed
Artificial Intelligence, Part 3: Improving Communication to Impact Patient Behavior
Artificial Intelligence, Part 2: Human Interaction, Liability, and Patient Safety
Deals, Dupixent and GLP-1 drug shortages
First ever CRISPR gene therapy approval: What happens next?
Artificial Intelligence, Part 1: Bias, Access, ROI, Potential Success and Failure
Zepbound vs Wegovy: A two horse race
Q3 earnings recap: Winners, losers & surprises